Skip to main content

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer

Project description

Novel inhibitor for metastatic prostate and pancreatic cancer

Metastases are the leading cause of death in most cancers including prostate and pancreatic cancer. Serine protease mesotrypsin promotes tumour invasion and metastasis in prostate and pancreatic cancer animal models, making it a potential therapeutic target. In the current EU-funded PROT-RESIST project, researchers designed a novel mesotrypsin inhibitor (APPI-3M) based on the human amyloid β-protein precursor Kunitz protease inhibitor domain scaffold. Previously, this inhibitor demonstrated high affinity and binding specificity, improved proteolytic resistance and high potency in preclinical models of prostate cancer invasion and metastasis. This stage of the project will focus on the final lead optimisation of APPI-3M, followed by preparations for clinical translation as an antimetastatic therapeutic adjuvant.

Host institution

BEN-GURION UNIVERSITY OF THE NEGEV
Net EU contribution
€ 150 000,00
Non-EU contribution
No data

Beneficiaries (1)

BEN-GURION UNIVERSITY OF THE NEGEV
Israel
Net EU contribution
€ 150 000,00
Non-EU contribution
No data